Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.

Advances in medical sciences - 1 Sept 2023

Hekmatshoar Yalda, Karadag Gurel Aynur, Ozkan Tulin, Rahbar Saadat Yalda, Koc Asli, Karabay Arzu Zeynep, Bozkurt Sureyya, Sunguroglu Asuman

Abstract excerpt

PURPOSE: Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of BCR-ABL protein. Imatinib (IMA) is considered as the first line therapy in management of CML which particularly targets the BCR-ABL tyrosine kinase protein. However, emergence of resistance to IMA hinders its clinical efficiency. Hence, identifying novel targets for therapeutic approaches in CML treatment is of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Phenotype

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37421850
DOI: 10.1016/j.advms.2023.06.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.PMID 37421850Read ↗

Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.Semantic proximity Read ↗

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.Semantic proximity Read ↗

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylateSemantic proximity Read ↗

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.Semantic proximity Read ↗

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinibSemantic proximity Read ↗

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical RelevanceSemantic proximity Read ↗

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Semantic proximity Read ↗

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitorsSemantic proximity Read ↗

miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cellsSemantic proximity Read ↗

Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinibSemantic proximity Read ↗

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.